Keyword: Ono Pharmaceutical
Nobel laureate wants bigger PD-1 revenue cut; Takeda scouts buyers for Latin America business; Chinese genomics investor is forced out of U.S. firm.
Opdivo, the Bristol-Myers cancer drug co-developed with Japan’s Ono, is a global cash cow—but a Nobel winner behind the drug isn't happy with his cut.
Eisai starts pivotal BAN2401 Alzheimer's trial; AZ helps build new life sciences hub in China; Ono secures a chance to license British I-O programs.
Tasuku Honjo wins Nobel Prize for PD-1 research; Legend fires back at CAR-T data fabrication allegation; Takeda alumni demand more on Shire buyout.
Merck gets half of Lenvima's sales in $5.8 billion deal; Juno and WuXi's CAR-T JV got $90 million; FDA approved Taiwanese firm's HIV drug.
Officials in Japan have moved to swiftly cut the price on two top-selling cancer meds.
BMS forms new I-O deal with Ono, Eisai's Lenvima wins NICE nod in kidney cancer, Sanofi tries to dig out of Philippines Dengvaxia fallout.
Just a few months after Merck’s monster May for Keytruda, which featured three FDA approvals, the drugmaker is back with another green light.
Merck will pony up $625 million plus royalties on its blockbuster cancer med Keytruda to settle up its patent dispute with Opdivo-maker Bristol-Myers. The royalty stream could be "quite meaningful," one analyst said.
Opdivo was the first drug in the PD-1/PD-L1 inhibitor class to reach the market after its approval in Japan in 2014, but then followed Merck’s Keytruda by several months in winning an FDA approval—and the two drugs have seesawed for dominance ever since.
